Page last updated: 2024-09-03

n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine and panaxadiol

n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine has been researched along with panaxadiol in 1 studies

Compound Research Comparison

Studies
(n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine)
Trials
(n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine)
Recent Studies (post-2010)
(n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine)
Studies
(panaxadiol)
Trials
(panaxadiol)
Recent Studies (post-2010) (panaxadiol)
7911681044

Protein Interaction Comparison

ProteinTaxonomyn-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine (IC50)panaxadiol (IC50)
Hypoxia-inducible factor 1-alphaHomo sapiens (human)9.1

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P1

Other Studies

1 other study(ies) available for n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine and panaxadiol

ArticleYear
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
    Bioorganic & medicinal chemistry, 2012, Nov-15, Volume: 20, Issue:22

    Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship

2012